{"id":46297,"date":"2022-07-19T08:02:10","date_gmt":"2022-07-19T06:02:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/"},"modified":"2022-07-19T08:02:10","modified_gmt":"2022-07-19T06:02:10","slug":"sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/","title":{"rendered":"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile"},"content":{"rendered":"
\n

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC\u2019s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Cat\u00f3lica de Chile (PI Dr. Pablo Gonz\u00e1lez). Study results will provide scientific evidence to support SINOVAC\u2019s influenza vaccine immunogenicity and protection capacity.\n<\/p>\n

<\/a><\/p>\n

\nThis clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above. In total, there will be 1,600 volunteers recruited, half of whom will receive 1 dose of SINOVAC\u2019s inactivated quadrivalent influenza vaccine, and the other half will receive a different quadrivalent influenza vaccine commercially available in Chile. Children aged between 3 and 8 of both groups who haven\u2019t received any influenza vaccine will receive 2 doses of influenza vaccine. All of the participants will be observed for 28 days following the completed inoculation to evaluate vaccine safety. The upcoming clinical trial in Chile will provide further evidence on the efficacy and safety of SINOVAC\u2019s quadrivalent influenza vaccine.\n<\/p>\n

\nAbout SINOVAC<\/b>\n<\/p>\n

\nSinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.\n<\/p>\n

\nSINOVAC\u2019s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.\n<\/p>\n

\nThe COVID-19 vaccine, CoronaVac\u00ae, has been approved for use in more than 60 countries and regions worldwide. The Healive\u00ae, hepatitis A vaccine, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive\u00ae, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC\u2019s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.\n<\/p>\n

\nSINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1\u00ae, which has supplied the Chinese government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu\u00ae, to the Chinese government stockpiling program.\n<\/p>\n

\nSINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.\n<\/p>\n

\nFor more information, please see the Company\u2019s website at www.sinovac.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSinovac Biotech Ltd.
\n
PR Team
\n
pr@sinovac.com<\/a>\n<\/p>\n

\nICR Inc.
\n
Bill Zima
\n
U.S.: 1-646-308-1707
\n
william.zima@icrinc.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC\u2019s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Cat\u00f3lica de Chile (PI Dr. Pablo Gonz\u00e1lez). Study results will … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46297","6":"format-standard","7":"category-industry"},"yoast_head":"\nSINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC\u2019s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Cat\u00f3lica de Chile (PI Dr. Pablo Gonz\u00e1lez). Study results will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-19T06:02:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220718005845\/en\/1517337\/21\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile\",\"datePublished\":\"2022-07-19T06:02:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/\"},\"wordCount\":441,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005845\\\/en\\\/1517337\\\/21\\\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/\",\"name\":\"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005845\\\/en\\\/1517337\\\/21\\\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg\",\"datePublished\":\"2022-07-19T06:02:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005845\\\/en\\\/1517337\\\/21\\\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005845\\\/en\\\/1517337\\\/21\\\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/","og_locale":"en_US","og_type":"article","og_title":"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile - Pharma Trend","og_description":"BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC\u2019s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Cat\u00f3lica de Chile (PI Dr. Pablo Gonz\u00e1lez). Study results will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-19T06:02:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220718005845\/en\/1517337\/21\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile","datePublished":"2022-07-19T06:02:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/"},"wordCount":441,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220718005845\/en\/1517337\/21\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/","url":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/","name":"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220718005845\/en\/1517337\/21\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg","datePublished":"2022-07-19T06:02:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220718005845\/en\/1517337\/21\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220718005845\/en\/1517337\/21\/%E7%A7%91%E5%85%B4LOGO-%E6%A8%AA%E7%89%88-%E9%80%8F%E6%98%8E%E5%BA%95.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sinovac-initiates-clinical-trial-for-its-quadrivalent-influenza-vaccine-in-chile\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46297"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46297\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}